Selected research
Industry Research
Fast-Acting Insulin Analog Industry Research Report 2026
Market perspective
The global Fast-Acting Insulin Analog market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Fast-Acting Insulin Analog is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Fast-Acting Insulin Analog is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Fast-Acting Insulin Analog is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Fast-Acting Insulin Analog include Tonghua Dongbao Pharmaceutical, Sanofi, Novo Nordisk, The United Laboratories International Holdings, Eli Lilly and Company and Gan and Lee Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Fast-Acting Insulin Analog market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Fast-Acting Insulin Analog Market by Company
Tonghua Dongbao Pharmaceutical
Sanofi
Novo Nordisk
The United Laboratories International Holdings
Eli Lilly and Company
Gan and Lee Pharmaceuticals
Fast-Acting Insulin Analog Segment by Type
Insulin Aspart
Insulin Lispro
Insulin Glulisine
Fast-Acting Insulin Analog Segment by Application
Gestational Diabetes
Type 2 Diabetes
Type 1 Diabetes
Other Diabetes
Fast-Acting Insulin Analog Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fast-Acting Insulin Analog market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Fast-Acting Insulin Analog and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fast-Acting Insulin Analog.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Fast-Acting Insulin Analog manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Fast-Acting Insulin Analog by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Fast-Acting Insulin Analog in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Insulin Aspart
- Insulin Lispro
- Insulin Glulisine
Applications
- Gestational Diabetes
- Type 2 Diabetes
- Type 1 Diabetes
- Other Diabetes
Companies covered
- Tonghua Dongbao Pharmaceutical
- Sanofi
- Novo Nordisk
- The United Laboratories International Holdings
- Eli Lilly and Company
- Gan and Lee Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Fast-Acting Insulin Analog Market Size (2021-2032)
- 2.2.2 Global Fast-Acting Insulin Analog Sales (2021-2032)
- 2.2.3 Global Fast-Acting Insulin Analog Market Average Price (2021-2032)
- 2.3 Fast-Acting Insulin Analog by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Insulin Aspart
- 2.3.3 Insulin Lispro
- 2.3.4 Insulin Glulisine
- 2.4 Fast-Acting Insulin Analog by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Gestational Diabetes
- 2.4.3 Type 2 Diabetes
- 2.4.4 Type 1 Diabetes
- 2.4.5 Other Diabetes
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Fast-Acting Insulin Analog Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Fast-Acting Insulin Analog Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Fast-Acting Insulin Analog Revenue of Manufacturers (2021-2026)
- 3.4 Global Fast-Acting Insulin Analog Average Price by Manufacturers (2021-2026)
- 3.5 Global Fast-Acting Insulin Analog Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Fast-Acting Insulin Analog, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Fast-Acting Insulin Analog, Product Type & Application
- 3.8 Global Manufacturers of Fast-Acting Insulin Analog, Established Date
- 3.9 Global Fast-Acting Insulin Analog Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Tonghua Dongbao Pharmaceutical
- 4.1.1 Tonghua Dongbao Pharmaceutical Company Information
- 4.1.2 Tonghua Dongbao Pharmaceutical Business Overview
- 4.1.3 Tonghua Dongbao Pharmaceutical Fast-Acting Insulin Analog Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Tonghua Dongbao Pharmaceutical Fast-Acting Insulin Analog Product Portfolio
- 4.1.5 Tonghua Dongbao Pharmaceutical Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Fast-Acting Insulin Analog Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Fast-Acting Insulin Analog Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Novo Nordisk
- 4.3.1 Novo Nordisk Company Information
- 4.3.2 Novo Nordisk Business Overview
- 4.3.3 Novo Nordisk Fast-Acting Insulin Analog Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novo Nordisk Fast-Acting Insulin Analog Product Portfolio
- 4.3.5 Novo Nordisk Recent Developments
- 4.4 The United Laboratories International Holdings
- 4.4.1 The United Laboratories International Holdings Company Information
- 4.4.2 The United Laboratories International Holdings Business Overview
- 4.4.3 The United Laboratories International Holdings Fast-Acting Insulin Analog Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 The United Laboratories International Holdings Fast-Acting Insulin Analog Product Portfolio
- 4.4.5 The United Laboratories International Holdings Recent Developments
- 4.5 Eli Lilly and Company
- 4.5.1 Eli Lilly and Company Company Information
- 4.5.2 Eli Lilly and Company Business Overview
- 4.5.3 Eli Lilly and Company Fast-Acting Insulin Analog Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Eli Lilly and Company Fast-Acting Insulin Analog Product Portfolio
- 4.5.5 Eli Lilly and Company Recent Developments
- 4.6 Gan and Lee Pharmaceuticals
- 4.6.1 Gan and Lee Pharmaceuticals Company Information
- 4.6.2 Gan and Lee Pharmaceuticals Business Overview
- 4.6.3 Gan and Lee Pharmaceuticals Fast-Acting Insulin Analog Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Gan and Lee Pharmaceuticals Fast-Acting Insulin Analog Product Portfolio
- 4.6.5 Gan and Lee Pharmaceuticals Recent Developments
5 Global Fast-Acting Insulin Analog Market Scenario by Region
- 5.1 Global Fast-Acting Insulin Analog Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Fast-Acting Insulin Analog Sales by Region: 2021-2032
- 5.2.1 Global Fast-Acting Insulin Analog Sales by Region: 2021-2026
- 5.2.2 Global Fast-Acting Insulin Analog Sales by Region: 2027-2032
- 5.3 Global Fast-Acting Insulin Analog Revenue by Region: 2021-2032
- 5.3.1 Global Fast-Acting Insulin Analog Revenue by Region: 2021-2026
- 5.3.2 Global Fast-Acting Insulin Analog Revenue by Region: 2027-2032
- 5.4 North America Fast-Acting Insulin Analog Market Facts & Figures by Country
- 5.4.1 North America Fast-Acting Insulin Analog Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Fast-Acting Insulin Analog Sales by Country (2021-2032)
- 5.4.3 North America Fast-Acting Insulin Analog Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Fast-Acting Insulin Analog Market Facts & Figures by Country
- 5.5.1 Europe Fast-Acting Insulin Analog Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Fast-Acting Insulin Analog Sales by Country (2021-2032)
- 5.5.3 Europe Fast-Acting Insulin Analog Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Fast-Acting Insulin Analog Market Facts & Figures by Country
- 5.6.1 Asia Pacific Fast-Acting Insulin Analog Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Fast-Acting Insulin Analog Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Fast-Acting Insulin Analog Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Fast-Acting Insulin Analog Market Facts & Figures by Country
- 5.7.1 South America Fast-Acting Insulin Analog Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Fast-Acting Insulin Analog Sales by Country (2021-2032)
- 5.7.3 South America Fast-Acting Insulin Analog Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Fast-Acting Insulin Analog Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Fast-Acting Insulin Analog Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Fast-Acting Insulin Analog Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Fast-Acting Insulin Analog Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Fast-Acting Insulin Analog Sales by Type (2021-2032)
- 6.1.1 Global Fast-Acting Insulin Analog Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Fast-Acting Insulin Analog Sales Market Share by Type (2021-2032)
- 6.2 Global Fast-Acting Insulin Analog Revenue by Type (2021-2032)
- 6.2.1 Global Fast-Acting Insulin Analog Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Fast-Acting Insulin Analog Revenue Market Share by Type (2021-2032)
- 6.3 Global Fast-Acting Insulin Analog Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Fast-Acting Insulin Analog Sales by Application (2021-2032)
- 7.1.1 Global Fast-Acting Insulin Analog Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Fast-Acting Insulin Analog Sales Market Share by Application (2021-2032)
- 7.2 Global Fast-Acting Insulin Analog Revenue by Application (2021-2032)
- 7.2.1 Global Fast-Acting Insulin Analog Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Fast-Acting Insulin Analog Revenue Market Share by Application (2021-2032)
- 7.3 Global Fast-Acting Insulin Analog Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Fast-Acting Insulin Analog Value Chain Analysis
- 8.1.1 Fast-Acting Insulin Analog Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Fast-Acting Insulin Analog Production Mode & Process
- 8.2 Fast-Acting Insulin Analog Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Fast-Acting Insulin Analog Distributors
- 8.2.3 Fast-Acting Insulin Analog Customers
9 Global Fast-Acting Insulin Analog Analyzing Market Dynamics
- 9.1 Fast-Acting Insulin Analog Industry Trends
- 9.2 Fast-Acting Insulin Analog Industry Drivers
- 9.3 Fast-Acting Insulin Analog Industry Opportunities and Challenges
- 9.4 Fast-Acting Insulin Analog Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst